Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?

@article{Stanczyk2014UseOM,
  title={Use of medroxyprogesterone acetate for hormone therapy in postmenopausal women: Is it safe?},
  author={F. Stanczyk and B. Bhavnani},
  journal={The Journal of Steroid Biochemistry and Molecular Biology},
  year={2014},
  volume={142},
  pages={30-38}
}
Medroxyprogesterone acetate (MPA) has been in clinical use for over 30 years, and was generally considered to be safe until the results of long-term studies of postmenopausal hormone therapy (HT) using treatment with conjugated equine estrogens (CEE) combined with MPA and CEE alone suggested that MPA, and perhaps other progestogens, may play a role in the increased risk of breast cancer and cardiovascular diseases. This review examines critically the safety of MPA in terms of breast cancer and… Expand
A comparative characterization of estrogens used in hormone therapy via estrogen receptor (ER)-α and -β
The other side of progestins: effects in the brain.
Confronting the challenges of the menopausal transition
...
1
2
...

References

SHOWING 1-10 OF 70 REFERENCES
Medroxyprogesterone acetate therapy in advanced breast cancer: the predictive value of androgen receptor expression.
...
1
2
3
4
5
...